Implementing A New CEO Strategy With NervGen's Adam Rogers, M.D. And Rich Macary
About this episode
This episode features a discussion with NervGen leaders about their new neuroreparative peptide and the company's strategic direction under new CEO Adam Rogers, M.D.
We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we talk with NervGen leaders Adam Rogers, M.D., and Rich Macary about NVG-291, a daily neuroreparative peptide designed to restore function in patients with spinal cord injuries. Adam talks about his strategy for the company after becoming CEO last July, including moving company trading from Canada's TSX Venture Exchange to the NASDAQ for better visibility, and making key hires for growt...
More episodes of Business Of Biotech
- The Impact Of FDA Risk On Biotech Rewards With CFO And Board Director Allan Shaw
- Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.
- Radiotherapeutics For Neuroendocrine Tumors With Perspective Therapeutics' Thijs Spoor
- Investing In Early-Stage Oncology With Yosemite's Dan McHugh
- Commercializing CAR T Cell Therapy With Legend Biotech's Alan Bash
- Radiotherapeutics For CNS Cancers With Plus Therapeutics' Marc Hedrick, M.D.
Explore listener stats, chart rankings, contacts and more on the Business Of Biotech podcast page.